# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 471-480 of 574 results.
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
Status: Recruiting
Last Changed: Dec 17, 2019
First Received: Aug 09, 2013
Disease(s): B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma, T-Cell Non-Hodgkin Lymphoma
Intervention(s): Ipilimumab, Lenalidomide
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Safety Study of SEA-CD40 in Cancer Patients
Status: Recruiting
Last Changed: Aug 04, 2020
First Received: Mar 03, 2015
Disease(s): Cancer, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hematologic Malignancies, Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Melanoma, Neoplasms, Neoplasm Metastasis, Neoplasms, Head and Neck, Neoplasms, Squamous Cell, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, Squamous Cell Cancer, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Neoplasm, Lymphoma, Non-Hodgkin, Pancreatic Adenocarcinoma
Intervention(s): Intravenous (IV) SEA-CD40, Pembrolizumab, Subcutaneous (SC) SEA-CD40, Gemcitabine, Nab-paclitaxel
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Rush University Medical Center, Chicago, Illinois, United States
University of Chicago Medical Center, Chicago, Illinois, United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
... and 8 other locations.
Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma
Status: Recruiting
Last Changed: Aug 05, 2020
First Received: Mar 21, 2019
Disease(s): Chronic Lymphocytic Leukemia, Richter Syndrome, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Indolent Non-hodgkin Lymphoma, Loss of Chromosome 17p, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, TP53 Gene Mutation
Intervention(s): Copanlisib, Nivolumab
Locations: City of Hope Medical Center, Duarte, California, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
OHSU Knight Cancer Institute, Portland, Oregon, United States
Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
Status: Recruiting
Last Changed: Sep 29, 2020
First Received: Feb 24, 2020
Disease(s): Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Advanced Solid Tumor, Non-small Cell Lung Cancer, Metastatic Melanoma
Intervention(s): BGB-10188, Zanubrutinib, Tislelizumab
Locations: Monash Hospital - Hematology, Clayton, Australia
St. Vincent Hospital - Sydney - Hematology/Oncology, Darlinghurst, Australia
Austin Hospital - Hematology, Heidelberg, Australia
Perth Blood Institute, West Perth, Australia
Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1)
Status: Recruiting
Last Changed: Jun 18, 2020
First Received: Nov 02, 2016
Disease(s): Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle-Cell Lymphoma, Diffuse Large B Cell Lymphoma
Intervention(s): CLR 131 single dose, CLR 131 multiple dose, CLR 131 fractionated dose
Locations: Cellectar Biosciences site, Redlands, California, United States
Cellectar Biosciences site, Jacksonville, Florida, United States
Cellectar Biosciences site, Maywood, Illinois, United States
Cellectar Biosciences site, Warrenville, Illinois, United States
Cellectar Biosciences site, Westwood, Kansas, United States
... and 6 other locations.
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
Status: Recruiting
Last Changed: Aug 31, 2020
First Received: Aug 28, 2017
Disease(s): Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, High Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Richter's Syndrome, B-cell Non-Hodgkin Lymphoma, T-cell Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Multiple Myeloma
Intervention(s): AZD4573
Locations: Research Site, Aachen, Germany
Research Site, Bonn, Germany
Research Site, Göttingen, Germany
Research Site, Heidelberg, Germany
Research Site, Ulm, Germany
... and 8 other locations.
Allo HSCT Using RIC for Hematological Diseases
Status: Recruiting
Last Changed: Sep 25, 2019
First Received: Jan 21, 2016
Disease(s): Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma, Myeloproliferative Syndromes, Hematological Diseases
Intervention(s): Allopurinol, Fludarabine, Cyclophosphamide, ATG, TBI, Tacrolimus, MMF, Peripheral Blood Stem Cells, Related or Unrelated Bone Marrow Cells
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Status: Recruiting
Last Changed: Sep 11, 2019
First Received: Jan 30, 2017
Disease(s): Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma
Intervention(s): Cryosurgery, Dendritic Cell Therapy, Pembrolizumab, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment
Locations: Mayo Clinic, Rochester, Minnesota, United States
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Status: Recruiting
Last Changed: Mar 17, 2020
First Received: Mar 28, 2019
Disease(s): Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors
Intervention(s): SL-279252
Locations: The Sarah Cannon Research Institute, Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Leuven Cancer Institute, Leuven, Belgium
Princess Margaret Cancer Center, Toronto, Ontario, Canada
Vall d'Hebron Institut D' Oncologia, Barcelona, Spain
... and 1 other locations.
A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML
Status: Recruiting
Last Changed: Jun 12, 2020
First Received: Jun 06, 2018
Disease(s): Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
Intervention(s): voruciclib
Locations: Dana Farber Cancer Institute, Boston, Massachusetts, United States
New York University, New York, New York, United States
Duke University, Durham, North Carolina, United States
Oregon Health and Science University, Portland, Oregon, United States
MD Anderson, Houston, Texas, United States
... and 3 other locations.